Other news to note
Monday, December 16, 2013
Bind Therapeutics Inc., of Cambridge, Mass., and Amgen Inc., of Thousand Oaks, Calif., amended their development and commercialization collaboration agreement to extend the period during which Amgen may exercise its option by six months.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.